04:55 PM EDT, 07/31/2025 (MT Newswires) -- Knight Therapeutics ( KHTRF ) on Thursday said it submitted a supplemental regulatory submission to Brazilian regulators for its MINJUVI drug for follicular lymphoma (FL).

The supplemental application was selected for review under Project Orbis and combines MINJUVI with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma.

"If approved, the combination of tafasitamab, rituximab and lenalidomide will be an important new therapeutic option for eligible adult patients with previously treated FL in Brazil. We look forward to continuing to work towards regulatory submissions in additional countries in Latin America over the next months," chief executive Samira Sakhia, said.

Shares of Knight Therapeutics ( KHTRF ) closed up $0.02 to $6.09 on the Toronto Stock Exchange and are up 16% year-to-date.